Friday, Jan. 25, 2019 Investigational Monoclonal Antibody to Treat Ebola is Safe in Adults The NIAID-developed investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. The trial took place at the NIH Clinical Center and enrolled 18 healthy adults. The monoclonal antibody is currently being offered to Ebola patients in the Democratic Republic of the Congo under compassionate use and as part of a Phase 2/3 clinical trial. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107